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Backgrounds and Aims: Molecular-targeted agents are acceptable standards to treat 
advanced-stage hepatocellular carcinoma (HCC), however, their therapeutic benefit, ie, 
sorafenib, was significantly offset in case of major vessel invasion. Liver-directed concurrent 
chemo-radiotherapy (LD-CCRT) provided favorable outcomes in terms of survivals and 
tumor shrinkage, so, we appraised its long-term therapeutic efficacy.
Patients and Methods: Advanced HCC patients with portal vein invasion (main trunk or 
the 1st order branch) were enrolled. During a 5-week radiotherapy course, concurrent hepatic 
arterial infusion chemotherapy (HAIC) with 5-fluorouracil and leucovorin was administered 
through an implanted port on the first and last 5 days. Four weeks after LD-CCRT, 
a maintenance HAIC using 5-fluorouracil and cisplatin was administered every 4 weeks.
Results: Among 152 patients, the objective response rates as the best response by modified 
Response Evaluation Criteria In Solid Tumors were 48.0% after LD-CCRT and 55.3% during 
subsequent HAIC maintenance. After LD-CCRT, biological responses in alpha-fetoprotein and 
protein induced by the absence of vitamin K or antagonist-II levels were achieved in 46.2% and 
52.6%, respectively. Sixteen patients (10.5%) underwent curative resection or liver transplantation 
after down-staging. Median overall survival and progression-free survival were 13.5 and 6.9 
months, respectively.
Conclusion: LD-CCRT followed by maintenance HAIC yielded favorable survival outcomes 
in advanced HCC patients with major portal vein invasion. Through initial tumor reduction, LD- 
CCRT induced down-staging with subsequent curative treatment feasible in 10.5% of patients, 
resulting in long-term survival. Further prospective trials are warranted to confirm these results.
Keywords: hepatocellular carcinoma, portal vein invasion, concurrent chemoradiotherapy, 
prognosis, response
Plain Language Summary
-Treatment options other than molecular-targeted agents are still limited for advanced stage- 
hepatocellular carcinoma (HCC) with major portal vein invasion.
-We assessed their survival outcomes undergoing liver-directed concurrent chemoradiother-
apy (LD-CCRT) followed by maintenance hepatic arterial infusion chemotherapy (HAIC).
-Among 152 patients, median overall survival and progression-free survival were 13.5 and 6.9 
months, respectively. The objective response rates as the best response by modified Response 
Evaluation Criteria in Solid Tumors were 48.0% after LD-CCRT and 55.3% during the planned 
Correspondence: Dai Hoon Han  
Department of Surgery, Yonsei University 
College of Medicine, 50-1 Yonsei-Ro, 
Seodaemun–Gu, Seoul 03722, Republic of 
Korea  
Tel +82-2-2228-2139  
Fax +82-2-313-8289  
Email dhhan@yuhs.ac   
Beom Kyung Kim  
Department of Internal Medicine, Yonsei 
University College of Medicine, 50-1 Yonsei- 
ro, Seodaemun–gu, Seoul 03722, Republic of 
Korea  
Tel +82-2-2228-1930  
Fax +82-2-393-6884  
Email beomkkim@yuhs.ac
submit your manuscript | www.dovepress.com Journal of Hepatocellular Carcinoma 2020:7 403–412                                                        403
http://doi.org/10.2147/JHC.S276528 
DovePress © 2020 Han et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Journal of Hepatocellular Carcinoma                                                    Dovepress
open access to scientific and medical research
Open Access Full Text Article
treatment course. After LD-CCRT, biological responses in alpha- 
fetoprotein and protein induced by the absence of vitamin K or 
antagonist-II levels were achieved in 46.2% and 52.6%, respectively. 
Sixteen patients (10.5%) underwent curative resection or liver trans-
plantation after down-staging.
- LD-CCRT followed by maintenance HAIC yielded favor-
able survival outcomes in advanced stage-HCC patients with 
major portal vein invasion. Through initial tumor reduction, 
LD-CCRT induced down-staging with subsequent curative treat-
ment feasible in 10.5% of patients. Further prospective trials are 
warranted to confirm these results.
Introduction
Approximately 10–40% of hepatocellular carcinoma 
(HCC) patients are diagnosed at an advanced stage with 
major portal vein (PV) tumor invasion. The expected 
prognosis in such cases is typically poor, despite the 
administration of optimal systemic therapy according to 
the best practice guidelines.1–3 Sorafenib is the first 
approved oral multi-kinase inhibitor for prolonging the 
overall survival (OS) of patients with advanced-stage 
HCC. Along with lenvatinib, it is currently regarded as 
the standard of care.1,3,4 However, data supporting the 
survival benefits from molecular-targeted agents among 
patients with advanced-stage HCC with major PV invasion 
are still limited. For example, among patients treated with 
sorafenib,5 the OS markedly decreased from 14.3 to 5.7 
months in case of extrahepatic spread and/or macrovascu-
lar invasion.6–8 Furthermore, although the median OS 
reached approximately 13 months in the Phase III trial 
comparing lenvatinib and sorafenib as the first-line treat-
ment for advanced-stage HCC, patients with major PV 
invasion at baseline were primarily excluded in that 
phase III trial. Thus, there is a pressing need for more 
effective treatment strategies in these patients. Recently, 
we could observe many literatures indicating that alterna-
tive strategies including loco-regional treatment (LRT) 
could improve survival outcomes compared to molecular- 
targeted agents alone.1,9,10
Among various LRTs, external beam radiation therapy 
(EBRT) has become widely popular primarily due to techno-
logical advances, including the introduction of 3-dimensional 
conformal radiation therapy (3D-CRT) and more recently, 
intensity-modulated radiotherapy (IMRT).11,12 These technol-
ogies allow the delivery of high tumoricidal radiation doses 
with minimal risk of damage to adjacent non-tumorous tissues. 
As a result, a high-dose EBRT for advanced HCC can lead to 
a long-lasting local tumor control as well as a higher 
probability of down-staging which allows curative resection 
or OLT with improved survival, in comparison with historical 
controls.12–14 According to several observational studies, 
liver-directed concurrent chemoradiotherapy (LD-CCRT) for 
advanced-stage HCC was associated with the favorable clin-
ical outcomes.15–17 In particular, Kim et al16 reported that the 
objective response rates (ORR) during the LD-CCRT-based 
treatment course was up to 53.2% and that 19.1% underwent 
curative resection or transplantation after down-staging, in 
contrast to only a minimal tumor shrinkage effect by sorafenib, 
ie at least about 2 ~5%.18,19 Another studies also supported 
anti-tumor effect by an intra-arterial infusion of 5-fluorouracil 
with or without EBRT.20–25
Based on the available evidence that effective initial 
tumor shrinkage by LD-CCRT may facilitate subsequent 
treatments with curative intent among advanced-stage 
HCC patients with major PV invasion, we aimed to assess 
clinical outcomes of LD-CCRT, in terms of not only sur-
vival outcomes but ORR and the proportion of conversion 
to curative treatment, of LD-CCRT.
Patients and Methods
Participants and Treatments
Patients who underwent LD-CCRT for advanced-stage 
HCC between 2011 and 2016 at Severance Hospital, 
Seoul, Republic of Korea, were retrospectively analyzed. 
HCC was diagnosed by histological or radiological eva-
luation with reference to the international 
guidelines.1,3,26,27 The eligibility criteria for LD-CCRT 
are described in Table 1. For example, LD-CCRT was 
not performed for patients with diffuse or multifocal bi- 
lobal tumors which cannot be included in a technically 
feasible RT field from the viewpoint of safety based upon 
liver function and radiation dosage to organs. In addition, 
the exclusion criteria were also described in Table 1.
LD-CCRT and subsequent maintenance HAIC were per-
formed according to the previous studies by Kim et al16 and 
Park et al28 respectively. Provided that patients have intrahe-
patic lesions eligible for transarterial chemo-embolization 
(TACE),29–31 they could be included in the study at physi-
cians’ discretion. The overall process of the treatment deliv-
ery was described in the Supplementary Table 1.
This study protocol was performed in accordance with 
the ethical guidelines of the 1975 Declaration of Helsinki 
and approved by the institutional review board (IRB) of 
Severance Hospital. The informed consent was waived 
because of the retrospective nature of the study. All patient 
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identifiers were removed once the data from the patient 
medical record is collected.
Follow-Up
Treatment responses were assessed approximately 1 
month after the completion of LD-CCRT and then every 
8 ~ 12 weeks, using modified Response Evaluation 
Criteria in Solid Tumors (mRECIST).32 During follow 
up, patients who successfully achieved down-staging 
underwent curative surgical resection or orthotropic liver 
transplantation (OLT) under a multi-disciplinary 
approach.33 Such approaches were considered, when com-
plete response (CR) or partial response (PR) by 
mRECIST32 was achieved and serum alpha-fetoprotein 
(AFP) and protein induced by the absence of vitamin 
K or antagonist-II (PIVKA-II) decreased to <20 ng/mL 
and <40 mAU/mL, respectively, through the 
treatment.15,34 Tumor resectability was determined in 
a multi-disciplinary approach through reviewing CT 
scans before and during the treatment.35 All gross lesions 
should be resected with a clear margin based on radiolo-
gical image. The resection type was determined based on 
functional reserve of the liver (FRL) and patient’s perfor-
mance status. For major liver resection defined as the 
resection of ≥3 anatomical segments, at least 40% of the 
total liver volume should be required as a future FRL. 
OLT was considered for patient with deteriorating liver 
function; those with pre-operative total bilirubin ≥2mg/dL 
or platelet counts <100,000/μL, or with future remnant 
liver volume/total liver volume <30% were considered 
for OLT.
The primary endpoint was the OS, and the secondary 
endpoints were progression-free survival (PFS), ORR 
(defined as the rate of CR or PR), and the proportion of 
patients undergoing curative surgical resection or OLT 
after down-staging. Patients were evaluated for any treat-
ment-related adverse event throughout the planned treat-
ment period. Adverse events were noted as per the 
standards and terminology set by the Cancer Therapy 
Evaluation Program’s Common Terminology Criteria for 
Adverse Events version 4.03.
Statistical Analysis
Data are expressed as mean ± standard deviation, median 
(interquartile range [IQR]) or number (%). Differences 
among categorical variables were analyzed for statistical 
significance with chi-square test (or Fisher’s exact test, if 
appropriate), respectively. Survival outcome was esti-
mated using Kaplan–Meier analysis with a comparison 
by Log rank test. Hazard ratios (HR) were calculated 
using Cox regression analysis. OS was calculated as the 
time interval from the date of treatment initiation to the 
date of death, whereas PFS was calculated as the time 
interval from the date of treatment initiation to the date 
of progression, or any kind of death in the absence of 
confirmed progression. The Statistical analyses were per-
formed using IBM® SPSS® Statistics Version 25.0 (IBM 
Corporation in Armonk, NY, US). All statistical tests 
with p-value of <0.05 were considered as significant.
Results
Patient Characteristics
In total, 152 patients with major PV invasion who under-
went LD-CCRT were analyzed (Supplementary Figure 1). 
Table 1 Patients’ Enrollment
Eligibility Criteria for LD-CCRT
Age 20–75 years
At least one unidimensional lesion measurable according to the 
modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Preserved liver function with a Child-Pugh score ≤ 7
Eastern Cooperative Oncology Group (ECOG) performance status 
score: 0 or 1
White blood cell count ≥ 3000/µL
Absolute neutrophil count ≥ 750/µL
Platelet count ≥ 60×103/µL
Serum alanine aminotransferase level < 10 times the upper limit of the 
normal range
Serum creatinine level ≤2.0 mg/dL
Primary tumor confined to a technically feasible RT field, without 
diffuse intra-hepatic spread
Exclusion criteria enrollment
History of other anti-cancer treatment for HCC after the diagnosis of 
advanced-stage HCC
Presence of extrahepatic metastasis
Other uncontrolled comorbidities or malignant neoplasm
Prior organ transplant
Active peptic ulcer
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Baseline characteristics are summarized in Table 2. The 
median age was 56 years (IQR 50–63 years), and the 
patients were predominantly male (90.1%). Chronic hepa-
titis B virus (HBV) infection was the most common etiol-
ogy (84.9%), and 127 (83.6%) patients had cirrhosis at 
enrollment. The majority of patients (128 [84.2%]) 
belonged to Child-Pugh A, but 15.8% had Child-Pugh B.
The median size of the largest HCC was 8.8 cm (IQR 
6–8.8 cm), and 46 patients (30.3%) had ≥5 tumors. There 
were 57 (37.5%) patients with tumor invasion into Vp4 
and 95 (62.5%) with tumor invasion into Vp3. Eighty-two 
(53.9%) patients had infiltrative tumor morphology.36–38 
Only 7 (4.6%) patients had direct tumor invasion into the 
inferior vena cava (IVC) and/or right atrium. The median 
AFP and PIVKA-II levels were 1655.5 (IQR 38–21,591) 
ng/mL and 2000 (IQR 266–2167) mAU/mL, respectively.
Treatment Delivery and Responses
Four weeks after LD-CCRT, the ORR was 48.0%. 
Subsequently, patients underwent a median of 4 (IQR 2–6) 
cycles of HAIC. During the planned treatment courses, the 
ORR as their best responses increased to 55.3% (Table 3). 
Among a subgroup (n=56) undergoing TACE before the start 
of LD-CCRT, the ORRs 4 weeks after LD-CCRT and during 
the planned treatment courses were 55.4% and 62.5%, respec-
tively. Radiological responses of malignant portal vein throm-
bosis as a non-measurable lesion by mRECIST32 4 weeks after 
LD-CCRT were as follows; CR (n=2, 1.3%), PR (n=52, 
34.2%), stable disease (n=85, 55.9%), and progressive disease 
(n=13, 8.6%). During the planned treatment courses, they were 
2.0% (n=3), 37.5% (n=57), 52.0% (n=79), and 8.6% (n=13), 
respectively.
Four weeks after LD-CCRT, 46.1% and 52.6% had favor-
able biological response (defined as a ≥ 50% decrease in 
tumor marker from the baseline) by AFP and PIVKA-II, 
respectively. During the planned treatment courses, they 
were 65.1% and 65.8%, respectively. In detail, from the 
baseline (median 1656 ng/mL, IQR [38–21,591]). The AFP 
level significantly decreased to 553 ng/mL (IQR 22 ~ 5282) 4 
weeks after LD-CCRT and 50 (8 ~ 1793) during the planned 
treatment courses (both p<0.001 by Wilcoxon signed ranks 
test). Likewise, from the baseline (median 2000 mAU/mL, 
[IQR 266–2167]), the PIVKA-II level significantly 
decreased to 257 mAU/mL (IQR 41 ~ 2000) 4 weeks after 
LD-CCRT and 76 mAU/mL (29 ~ 1019) during the planned 
treatment courses (both p<0.001 by Wilcoxon signed ranks 
test). Detailed changes in tumor size and their correlations 
with tumor markers were described in waterfall plots 
(Supplementary Figure 2A, 2B, and 2C) and the association 
between radiological and biological responses were summar-
ized in Supplementary Table 2 and Supplementary Figure 3.).
Notably, during the planned treatment courses, 16 
patients (10.5%) underwent curative resection or OLT 
after successful down-staging. The median time from the 
initiation of LD-CCRT to the last follow-up among these 
16 patients was 34.8 (IQR 21.1–60.9) months. Seven cases 
of death were observed between 7.2 and 61.6 months 
(median 22.0 months, IQR 15.0–59.0 months). Overall, 
there was no post-operative complication of > grade III 
by the Clavien-Dindo classification,39 except one post- 
OLT mortality. There was one intra-operative complication 
Table 2 Characteristics of the Study Patients (n=152)
Variables





Child-Pugh class A/B 128(84.2%)/24(15.8%)
ALBI grade 1/2/3 34 (22.4%)/110 (72.3%)/8(5.3%)
ALBI score -2.21 (-2.54 ~ -1.89)
Performance status, ECOG 0/1 82(53.9%)/70(46.1%)




Depth of portal vein invasion
Vp3/Vp4 95(62.5%)/57(37.5%)
Infiltrative tumor morphology 82 (53.9%)





AFP (ng/ml) 1656 (38–21591)
PIVKA-II (mAU/ml) 2000 (266–2167)
White blood cells (×103/µl) 5.63 (4.53–7.16)
Hemoglobin (g/dL) 12.9 (11.6–13.9)
Platelet count (×103/µl) 153.5 (111–209)
ALT (IU/L) 37 (23–56)
Albumin (g/dL) 3.5(3.2–3.9)
Total bilirubin (mg/dL) 0.8 (0.6–1.1)
Prothrombin time-INR 1.07 (1.0–1.15)
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; IVC, inferior vena 
cava; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or 
antagonist-II; ALT, alanine aminotransferase; INR, international normalized ratio.
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of weak pulsation after hepatic artery anastomosis during 
living donor OLT, for which the anastomosis of right 
hepatic artery of the graft to the common hepatic artery 
of the recipient was switched to transposition anastomosis 
with the left gastric artery of the recipient; this patient had 
no significant post-OLT complication. Two patients devel-
oped biliary strictures most likely 6 months after OLT, 
both of which were successfully treated with the endo-
scopic and/or percutaneous approaches. Among patients 
undergoing surgical resection, there was no significant 
post-operative complication; 5 patients developed the 
small amount of pleural effusion, all of which resolved 
spontaneously without any intervention.
Survival Outcomes and Prognosis Factors
Overall, a total of 107 patients died and the median OS 
was 13.5 months (95% confidence interval [CI] 11.003–-
16.077) (Figure 1). The median PFS was 6.9 months 
(95% CI 6.326–7.474) (Figure 2). Treatment modalities 
after progression of disease included continuing intra- 
arterial chemotherapy (6.1%), LRTs such as TACE or 
Transarterial chemoinfusion (TACI) (16.0%), and sys-
temic chemotherapy including systemic 5-fluorouracil 
plus cisplatin chemotherapy (9.9%) and sorafenib 
(23.7%). Palliative radiotherapy was delivered to patients 
with bone metastases (1.5%). The majority of patients 
with disease progression (32.2%) received supportive 
care.
Table 4 shows that only significant prognostic factor for OS 
was ALBI score (HR 1.523, 95% CI 1.032–2.246; p=0.034).
Subgroup Analysis for Patients with Elevated AFP or 
PIVKA-II Levels at Baseline
Among 126 (82.9%) patients with baseline AFP > 20 
ng/mL, 54.0% showed the favorable biological response 
4 weeks after LD-CCRT. Such AFP responders were 
more likely to have the higher ORR 4 weeks after LD- 
Table 3 Treatment Response










Biological Response 4 Weeks After LD-CCRT
AFP response 70 (46.1%)
PIVKA-II response 80 (52.6%)
Biological Response During the Planned Treatment Courses
AFP response 99 (65.1%)
PIVKA-II response 100 (65.8%)
Changes in AFP Level
4 weeks after LD-CCRT 553 (22 ~ 5282)*
During the planned treatment courses 50 (8 ~ 1793)*
Changes in PIVKA-II Level
4 weeks after LD-CCRT 257 (41 ~ 2000)*
During the planned treatment courses 76 (29 ~ 1019)*
Note: *All p<0.001 from each baseline level by Wilcoxon signed ranks test. 
Abbreviations: LD-CCRT, liver-directed concurrent chemoradiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, 
progressive disease; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II.
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CCRT (57.4% vs 34.5%, respectively; p=0.010 by chi- 
square test), and the longer OS (22.4 vs 10.8 months; 
p<0.001 by Log rank test) and PFS (9.0 vs 5.1 months; 
p=0.003 by Log rank test) than non-responders.
Likewise, among 137 (90.1%) patients with baseline 
PIVKA-II >40 mAU/mL, 58.4% showed the favorable 
biological response 4 weeks after LD-CCRT. Such 
PIKVA-II responders were more likely to have the higher 
ORR 4 weeks after LD-CCRT (65.0 vs 21.1%, respec-
tively; p<0.001 by chi-square test) and the longer OS 
(20.3 vs 11.5 months, respectively; p=0.001 by Log rank 
test) and PFS (7.7 vs 5.7 months, respectively; p=0.016 by 
Log rank test) than non-responders.
Subgroup Analysis for Patients with HBV-Related 
HCC
Among 129 patients with HBV-related HCC, the ORRs 4 
weeks after LD-CCRT and during the planned treatment 
courses were 49.6% and 55.8%, respectively. Likewise, 
43.4% and 53.5% had favorable biological response by AFP 
and PIVKA-II, respectively, 4 weeks after LD-CCRT. They 
were 63.6% and 65.9%, respectively, during the planned treat-
ment courses. The median OS and PFS were 14.1 (95% CI 
11.358–16.902) and 7.2 (95% CI 6.553–7.847) months, 
respectively.
Treatment-Related Adverse Events
Treatment-related adverse events during the planned treat-
ment schedules are summarized in Table 5. Three key 
events associated with RT for liver, ie ascites, hepatic 
encephalopathy, and melena were evaluated using the 
SOMA-LENT grading classification.40 Overall, deteriora-
tion in liver function (defined as a shift in Child-Pugh 
score by 2 or more points from the baseline) after LD- 
CCRT was observed in 46 patients (30.3%), while 38 
patients (25.0%) demonstrated newly developed ascites. 
Among 129 patients with chronic HBV infection, three 
patients (2.3%) developed virologic breakthrough, all of 
whom were treated with appropriate antiviral therapy.41 
After LD-CCRT, 32 patients (21.1%) developed radiation 
gastritis, while 16 patients (10.5%) experienced upper 
gastrointestinal bleeding, which was successfully managed 
with endoscopic hemostasis and medical management. 
Among patients receiving maintenance HAIC after LD- 
CCRT, HAIC was discontinued in one patient due to HCC 
Figure 1 Kaplan–Meier analysis of OS. Figure 2 Kaplan–Meier analysis of PFS.
Table 4 Prognostic Factors for Overall Survival
Variables HR (95% CI) p-value
Age 0.999 (0.980 - 1.018) 0.935
Male 1.073 (0.574 - 2.006) 0.826
Cirrhosis 1.461 (0.863 - 2.475) 0.158
Child-Pugh class B 1.528 (0.947 - 2.466) 0.082
ALBI score 1.523 (1.032 - 2.246) 0.034
Tumor size ≥ 10 cm 1.272 (0.864 - 1.874) 0.223
Number of tumors ≥4 1.194 (0.799 - 1.784) 0.386
Depth of portal vein invasion 
(Vp4)
1.242 (0.842 - 1.833) 0.275
Infiltrative tumor morphology 1.161 (0.789 - 1.707) 0.448
AFP ≥ 400 ng/ml 1.132 (0.770 - 1.666) 0.528
PIVKA-II ≥ 1000 mAU/ml 1.058 (0.724 - 1.548) 0.770
Platelet count, ×103/µl 1.000 (0.998 - 1.002) 0.938
Abbreviations: HR, hazard ratio; AFP, alpha-fetoprotein; PIVKA-II, protein 
induced by vitamin K absence or antagonist-II; INR, international normalized ratio.
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rupture, in one patient due to hepatic encephalopathy, and 
in two patients due to sepsis.
Discussion
HCC with major portal vein invasion has poor prognosis 
and the median OS among such patients is expected to 
range from 7 to 8.5 months according to the real-life 
experience in the Republic of Korea.2,8 An effective sys-
temic therapy is an important option for the treatment of 
HCC in the subset of patients with extrahepatic metastasis. 
However, considering that HCC is a rapidly growing 
locally aggressive disease frequently leading to the 
patients’ death before extrahepatic metastasis have devel-
oped, there has been various attempts to locally control the 
disease with LRTs, so far. For instance, the previous study 
showed that locally advanced HCC patients treated with 
LD-CCRT showed the higher ORRs at post-treatment 1 
(46.8% VS 16.1%, respectively, P<0.001) and 3 (39.3% vs 
21.4%, P=0.04) months than those treated with selective 
internal radiation therapy (SIRT), however, long-term 
response rates and survival rates were comparable.42 Two 
recent comparative trials comparing SIRT vs sorafenib in 
locally advanced HCC patients, ie SARAH and 
SIRveNIB, showed comparable median OS between the 
two treatment groups, but the response rate was higher in 
the SIRT as compared to sorafenib group, suggesting the 
potential of SIRT as more likelihood to control the tumor 
within the liver.18,43
In this study, we present locally advanced-stage HCC 
patients with major PV invasion receiving LD-CCRT with 
HAIC maintenance. Out of the total study population, 143 
patients (94.0%) had poor oncological prognostic factors, 
including massive tumor (≥10 cm), infiltrative tumor mor-
phology, tumor invasion into the main portal trunk (Vp4), 
tumor invasion into the IVC and/or right atrium, AFP level 
≥400 ng/mL, or PIVKA-II level ≥1000 mAU/mL. In this 
population, LD-CCRT followed by maintenance HAIC 
demonstrated encouraging results, not only producing an 
objective response in 55.3% of subjects but also improving 
the median OS to 13.5 months. The median OS of 13.5 
months in our study population with Vp3 or Vp4 invasion 
is notable given that patients with major PV invasion at 
baseline were excluded in that phase III trial. Even though 
our study is only a one-arm study with a retrospective design, 
our findings could at least reappraise the necessity of future 
prospective randomized clinical trials comparing the efficacy 
between active LRT and systemic chemotherapy in patients 
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portal vein invasion, LD-CCRT showed potential to convert 
unresectable HCC to resectable HCC. During the planned 
treatment courses, 10.5% of patients achieved successful 
down-staging from LD-CCRT and underwent curative resec-
tion or transplantation. The optimal treatment strategy for 
successful down-staging remains to be determined. Despite 
several positive results, repeated TACE alone is considered 
to be contraindicated in this population due to the potential of 
hepatic insufficiency resulting from ischemic insult.44–47 
HAIC may be an eligible LRT option; however, the evidence 
for its efficacy remains weak.25 EBRT is also complicated by 
issues of systemic or local failure outside the RT field, 
notwithstanding the excellent intra-RT field disease control 
rate. Our findings indicate that EBRT-based LRT may be 
a useful strategy for down-staging of advanced-stage HCC.48
Our treatment protocol for LD-CCRT has several 
advantages for the curative treatment for advanced-stage 
HCC. Most importantly, the FRL increased substantially 
after LD-CCRT,15 which is induced by a marked atrophy 
of the irradiated region and a compensatory enlargement 
of the non-irradiated region.49 Another advantage is that, 
optimal candidates for curative treatments could be 
selected through better assessment of the biological beha-
viors of advanced tumors during the period of so-called 
“neo-adjuvant” treatment. Finally, 5-fluorouracil could be 
useful as a radio-sensitizer for treating HCC as well as its 
anti-cancer effect;50–55 therefore, a synergistic effect 
against HCC might be expected. Although not all patients 
with advanced-stage HCC with major PV invasion would 
be eligible for EBRT-based active LRTs in real-world 
practice, the feasibility of EBRT-based active LRTs should 
be carefully assessed through a multi-disciplinary 
approach.
This study has several limitations. In the first place, it 
was a single-arm study with a retrospective design from the 
single institution and the higher proportion of male patients 
might be another problem, both of which can lead to selec-
tion bias. Therefore, additional multi-center, randomized 
controlled trials are required to prove the utility of LD- 
CCRT. However, our findings provided a rationale for 
further prospective clinical trials to assess the efficacy of 
alternative LRTs other than molecular-targeted agents alone 
as a recommended first-line modality in treating advanced- 
stage HCC with major PV invasion. Similarly, given that 
novel systemic agents such as atezolizumab plus bevacizu-
mab will presently become available in the clinical setting,56 
the potential benefits of induction LD-CCRT as a neo- 
adjuvant treatment should be studied further. Another 
limitation is that our results might not be generalizable to 
all HCC patients, since chronic HBV infection was the most 
predominant etiology among our study population.41,57,58 
Furthermore, there was limited availability of second-line 
systemic agents in South Korea during the study period. 
Additional long-term follow-up to evaluate the entire clin-
ical course of advanced-stage HCC is advisable.
Conclusion
In conclusion, LD-CCRT followed by maintenance HAIC 
demonstrated not only favorable outcomes through initial 
tumor size reduction but also acceptable tolerability in 
patients with advanced-stage HCC with major PV inva-
sion. To confirm these results, further prospective clinical 
trials are required.
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